The physicians and clinical research coordinators at Capital Allergy & Respiratory Disease Center have a strong commitment to clinical research. We have multiple ongoing clinical trials throughout the year.
If you are interested in participating in one of our studies, please feel free to call or e-mail our clinical research department for further information. Learn More about Clinical Research
Clinical Research Department
You may also submit your name to be considered for a study by filling out this online form
Patients who qualify for participation in these studies will be provided with free study medication, free study-related care, and possible monetary compensation.
Our current studies include:
This is a research study for people with Primary Immunodeficiency Disease receiving treatment with HyQvia. The main objective is to collect data on the long term safety of HyQvia as prescribed and administered in routine clinical practice. Once you qualify and have been enrolled in the study, your study visits will be conducted during your regular/routine clinic visits or at least every three months. The study is currently open to enrollment; if you meet certain criteria, you may qualify for the second phase which will last 2 additional years.
Some of the requirements to qualify for this study are: You must
- Require immunoglobulin treatment for PIDD
- Be aged 16 years or older; open to both males and females
- Have been prescribed or currently receiving treatment with HyQvia
- Not have Hypersensitivity to the drug, HyQvia
- Be willing to comply with study procedures
- Not participate in another interventional clinical study at the same time or within 30 days prior to enrollment
Please fill out the patient interest form if interested and a research team member will reach out to you shortly.
- AIRWISE – A randomized 12 month clinical trial comparing Stiolto Respimat vs triple therapy in the reduction of COPD exacerbations in patients with COPD.
- CHRONICLE Study – A longitudinal observational study of the characteristics, treatment patterns and health outcomes of individuals with severe asthma in the United States.
- CAPTAIN Study – A randomized 24-52 week clinical trial comparing the efficacy, safety and tolerability of a triple therapy drug in patients with moderately uncontrolled asthma.
- QAW039 – A randomized 12-week clinical trial to assess the efficacy and safety of an add-on therapy in adolescents and adults with uncontrolled asthma.